Merck bolstering oncology pipeline via $2.2 billion acquisition

22 May 2019
merck-big

US pharma giant Merck & Co (NYSE: MRK) announced yesterday that it will acquire privately held Peloton Therapeutics in a deal which could exceed $2.2 billion, and which would bring the company a late-stage kidney cancer candidate.

Peloton is a clinical-stage biopharmaceutical company focused on the development of novel small-molecule therapeutic candidates targeting hypoxia-inducible factor-2α (HIF-2α) for the treatment of patients with cancer and other non-oncology diseases. Peloton’s lead candidate is PT2977, a novel oral HIF-2α inhibitor in late-stage development for renal cell carcinoma (RCC).

The market for cancer drugs is estimated at$123 billion worldwide, with Merck's own blockbuster immunotherapy Keytruda (pembrolizumab) taking a handsome $7.2 billion stake last year, and gaining approval last month for treating renal cell cancer in the USA.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology